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Abstract
Oral squamous cell carcinoma (OSCC) is often associated with metastatic disease and a poor 5 year survival rate. Patients
diagnosed with small tumours generally have a more favourable outcome, but some of these small tumours are aggressive
and lead to early death. To avoid harmful overtreatment of patients with favourable prognosis, there is a need for predictive
biomarkers that can be used for treatment stratification. In this study we assessed the possibility to use components of the
plasminogen activator (PA) system as prognostic markers for OSCC outcome and compared this to the commonly used
biomarker Ki-67. A tissue-micro-array (TMA) based immunohistochemical analysis of primary tumour tissue obtained from a
North Norwegian cohort of 115 patients diagnosed with OSCC was conducted. The expression of the biomarkers was
compared with clinicopathological variables and disease specific death. The statistical analyses revealed that low expression
of uPAR (p = 0.031) and PAI-1 (p = 0.021) in the tumour cells was significantly associated with low disease specific death in
patients with small tumours and no lymph node metastasis (T1N0). The commonly used biomarker, Ki-67, was not
associated with disease specific death in any of the groups of patients analysed. The conclusion is that uPAR and PAI-1 are
potential predictive biomarkers in early stage tumours and that this warrants further studies on a larger cohort of patients.
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Introduction
Squamous cell carcinoma (SCC) is the most frequent malignant
tumour in the oral cavity, with a propensity to early and extensive
lymph node metastasis [1]. In most populations, the two major risk
factors are tobacco use and alcohol consumption, which seem to
function synergistically [2]. Prognosis is mainly determined by the
stage of the tumour at presentation [2], which is determined
according to the TNM-staging system: tumour size (T), regional
lymph node metastasis (N) and distant metastasis (M) [3]. Small
tumours without metastasis largely present with good prognosis
[4], however, there are substantial individual differences in the
response to treatment of patients belonging to the same TNM-
groups [3], mainly because of large heterogeneity of the tumours
[5]. The relationship between N status and prognosis has been
reported by numerous studies and most patients that present with
a lymph node metastasis will undergo therapeutic neck dissection
[2,6]. The controversy is whether patients with no lymph node
metastasis at diagnosis should be given the same treatment due to
high recurrence rate and the large number of occult metastases
[7,8]. Instead, a ‘‘watchful waiting’’ strategy is commonly used to
avoid overtreatment of patients. Hence, there is a great need for a
better prognostic tool to distinguish between patients with no
lymph node metastasis at the time of diagnosis (N0) that are in
need for adjuvant treatment, and those that can safely be
monitored with a ‘‘watchful waiting’’ strategy.
A long list of prognostic biomarkers has been suggested for
OSCC, but there is still a need for identification of new and robust
prognostic markers [5,9]. Some of the most promising were
epidermal growth factor receptor (EGFR), p53 and matrix
metalloproteinases (MMPs), though conflicting results exist
[4,5,10]. Also, constituents of the plasminogen activator (PA)
system have been suggested as promising biomarkers in OSCC
[11], and several proteins of the PA system have been shown to
correlate to poor prognosis [12–18].
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Cancer cells are thought to exploit the PA system and MMPs
during cancer invasion, enabling ECM degradation and cell
migration [19]. The key effector of the PA system, the serine
protease plasmin, is readily activated from its precursor plasmin-
ogen, by either urokinase plasminogen activator (uPA) or tissue
type plasminogen activator (tPA). tPA is primarily thought to be
involved in fibrinolysis, while uPA is mainly involved in wound
healing and cancer invasion. The proteolytic activity of uPA is
greatly enhanced by binding to its cell surface localized receptor
(uPAR) [20], which is often concentrated at the leading edge of
migrating cells [21]. Plasminogen activator inhibitor-1 (PAI-1) and
PAI-2 are involved in the regulation of uPA and tPA activity [22].
In addition to regulation of proteolysis, both uPAR and PAI-1
have roles directly linked to cell adhesion and migration through
their interactions with the extracellular matrix constituent
vitronectin [23,24].
In this study we assessed the possibility to use components of the
PA system as prognostic biomarkers for OSCC outcome and
compared this to Ki-67 which is a commonly used biomarker in
several cancers. The expression of the biomarkers in small tumours
with no lymph node metastasis at the time of diagnosis are of
particular interest, as this could help distinguish between patients
in need of additional treatment and those where less is better.
Materials and Methods
Ethics statement
The study was approved by the Regional Committees for
Medical and Health Research Ethics, Northern Norway (No. 22/
2007). The patient information was anonymized and de-identified
prior to analysis. The ethics committee deemed it unnecessary to
obtain written or oral consent from the participating patients.
Patients and specimens
From the archives of the Diagnostic Clinic, University Hospital
of North Norway, 160 patients with histologically verified
diagnoses of primary SCC of the oral cavity and the oropharynx
in the period 1986–2002 were selected. From this group, patients
with SCC of the oropharynx and with verrucous tumours, as well
as those who had received prior radiotherapy to the head and neck
area, were excluded from the study. The remaining specimens
represented biopsies and surgical resections (in some cases both)
from mobile tongue, floor of the mouth, bucca, gingiva and soft
palate from a total of 115 patients. Clinical data and tumour stage
according to TNM-classification [25] was retrieved from patients
files, pathology reports, Statistics Norway and the Cause of Death
Registry. The N and M statuses were determined by clinical and
radiological examination. The last day of follow up was January
1st, 2012. The normal tissues used as controls were anonymized
and obtained from the archives of the Diagnostic Clinic,
University Hospital of North Norway.
Tissue microarray (TMA)
Cores of 0.6 mm were taken from the representative tumour
tissue and inserted into a recipient paraffin block to create a tissue
microarray, using a Beecher Instruments Micro Tissue Arrayer.
Eight cores were taken per tumour and distributed pairwise into a
total of four parallel recipient microarray blocks (A, B, C and D).
Sections of 4 mm were cut and transferred to Superfrost+ slides for
immunohistochemical (IHC) analysis.
Immunohistochemistry
Sections of the TMA blocks were immunohistochemically
stained for the presence of uPAR, uPA, PAI-1, and Ki67. In
addition, normal buccal mucosa tissue (n = 5) was stained for
uPAR and PAI-1. The antibodies and staining conditions used are
listed in table 1. All TMAs were also stained for cytokeratin to
verify the presence of epithelial cancer tissue, and cores without
such tissue were withdrawn from the evaluation. After depar-
affinization in xylene, sections were rehydrated in graded alcohol
baths. The staining was performed essentially as previously
described [26], with some modifications as described below for
the various antibodies. Heat-induced epitope retrieval (HIER) was
performed on all sections prior to blocking of endogenous
peroxidase activity. All HIER was performed at 95–99uC for
20 minutes in 10 mM citrate buffer pH 6.0. Optimization of
pretreatment conditions was performed for each staining. A
negative control where the primary antibody was omitted was
included for all antibodies used and showed no staining in all cases.
uPAR
Subsequent to peroxidase blocking, sections were washed in
wash buffer A (Table 1). Unspecific antigen binding was blocked
using assay buffer (Table 1) with 10% goat serum (Dako North
America, Carpintera, CA, USA), which was also used for primary
antibody dilution. Sections were then washed in wash buffer A,
before the primary antibody was added. Subsequent washing was
performed in wash buffer B (Table 1) before the primary antibody
was detected (Table 1). The specificity of the monoclonal anti-
human uPAR antibody #3936 has been validated in several
studies [27–29], including using preadsorption of the antibody
with recombinant native soluble form of uPAR [27], or with
purified soluble uPAR from phospholipase C treated U937 cells
[29], which both resulted in strong reduction in staining of tumour
tissue. Carriero et al. also compared the performance of the
#3936 antibody to the polyclonal #399 anti-uPAR antibody, and
found good agreement between the staining obtained with the two
antibodies [28]. In addition, the specificity was validated using our
IHC protocol and on Western blotting as described in information
S1 and figure S1.
uPA and PAI-1
PBS w/1.5% goat serum was used for both antibody dilution as
well as blocking unspecific antigen binding. The specificity of the
anti-uPA antibody (Ab24121) was verified by staining pancreatic
cancer (Figure S2) and placenta tissue (data not shown) which are
known to be positive for uPA [30–32], and the specificity of the
anti-PAI-1 antibody (BT-BS3503) used was verified by staining
human placenta tissue (Figure S3) [32,33]. Descriptions of the
methods used and results are presented in information S1.
Ki-67 and Cytokeratin
The staining for both Ki-67 and Cytokeratin were performed at
the Diagnostic Clinic-Clinical Pathology at the University Hospital
of North Norway using the Ventana BenchMark XT automated
slide preparation system (Ventana Medical Systems, Inc., Tucson,
AZ). The accredited procedures were performed according to the
ISO/IEC 15189 standard.
Scoring methods
Several parallel cores from each tumour were stained. However,
for some markers, not all cores could be scored due to technical
issues, or due to the lack of tumour tissue, and were therefore not
included in the analysis. The mean number of evaluated cores per
marker was 4.75 for uPAR, 3.01 for uPA, 3.51 for PAI-1 and 2.00
for Ki-67. The scoring of the uPAR, uPA and PAI-1 staining was
semi-quantitative [34,35], and only cytoplasmic and cell mem-
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brane staining was recorded. The staining index (SI) was
calculated as a product of staining intensity (none (0), weak (1),
moderate (2) or strong (3)), and proportion of positive tumour cells
(none (0), ,10% (1), 10–50% (2), 51–80% (3) or .80% (4)). Thus,
the SI for each core differed from a minimum value of zero to a
maximum of 12. Each patient’s final score for each marker was the
mean SI of all cores evaluated. Scoring of the uPAR and PAI-1
staining of the normal buccal mucosa tissue was performed in the
same manner as for the tumour tissue. Ki-67 was scored in a
modified version as percentage of nuclei stained; 1 (,10%), 2 (10–
50%), 3 (.50%) [36]. All slides were scored by one pathologist
(SES) and one head and neck surgeon (OR). There was a good
agreement between observers as Spearman’s Rho correlation
coefficient was 0.753 and 0.881 (p,0.001) when tested on uPA
and uPAR scorings in random samples in 25% of the cases. A
correlation of deviation between the cores was 33.8% for uPA
which reflects the heterogeneity of the tumours.
Statistical analysis
The analyses were performed by using IBM SPSS statistics 19
for Windows (IBM Corporation Armonk, NY, USA). Cut-off
points were determined to obtain binary variables for statistical
analyses and were based on the median value of the final scores for
each marker. Values below the median point were designated low-
expression, while the values in the upper median part were
designated as high-expression. The cut-off value of the evaluated
markers was 5.63 for uPAR, 7.30 for uPA, 5.25 for PAI-1, and
2.00 for Ki-67. Associations between different categorical variables
were assessed with Pearson’s Chi-Square test, and one-way
analysis of variance (ANOVA) was used to compare means.
Univariate analyses of time from diagnosis to death were
performed using the Kaplan-Meier method, and differences
between categories were estimated by the log-rank test, with the
date of diagnosis as starting point. The multivariate analysis was
carried out using the Cox proportional hazards model. The
correlation analyses were done using Spearman’s Rho (2-tailed)
and presented as a Scatter plot with regression line and 95%
confidence interval lines. All results were considered significant if
p#0.05, and reported according to the REMARK guidelines by
McShane et al. [37].
Results
Clinical characteristics in relation to disease specific
death
Primary tumour tissue from 115 patients in a North Norwegian
cohort diagnosed with OSCC from 1986 to 2002 was analysed in
this retrospective study and the clinicopathological variables are
listed in table S1. A total of 64 males and 51 females with a median
age of 65 years were included in the study. From the official
records at Statistics Norway and the Cause of Death Registry it
was found that 42% of the male patients and 37% of the females
died a disease specific death within 5 years from diagnosis. Mean
overall survival was 53.9 months for men and 82.9 for women, and
the difference was statistically significant (p = 0.033). The mean
disease specific survival was also significantly shorter for men (80.8
months) than for women (128.2 months)(p = 0.019). Most patients
presented with moderately or well differentiated tumours which
were relatively small (T1 (34%) or T2 (37%)). In addition, 63% (72
out of 115) did not have any detectable lymph node metastasis,
indicating that the majority were diagnosed at an early disease
stage.
As expected, we found that tumour size (T-status) and lymph
node status correlated with both overall (data not shown) and
disease specific death (Table S1). In early stage disease, T1 vs T2–
T4 and N0 vs N+/unknown, showed that both of these variables
were significant in the multivariate analyses, with Hazard Ratio
2.665 (95% CI 1.224–5.804) for T-stage (p = 0.007), and 2.633
(95% CI 1.425–4.865) for N-stage (p = 0.002).
Table 1. Primary antibodies used for IHC.
Primary antibodies Dilution Wash buffer Detection
Mouse monoclonal anti-human
uPAR (#3936, Sekisui Diagnostica,
Stamford, CT, USA)
1:10, 4uC ON* Wash buffer A (PBS w/0.41 M NaCl,
0.3% Tween-20, pH 6.0). Assay buffer
(PBS w/1% BSA, 0.3% Tween-20, pH 6.0).
Wash buffer B (PBS w/0.41 M NaCl, 1%
BSA, 0.3% Tween-20, pH 6.0).
EnVision+ Dual Link system HRP (+DAB), for
rabbit and mouse primary antibody
detection (Dako; Glostrup, Danmark).
Rabbit polyclonal anti-human uPA
(Ab24121, Abcam Inc., Cambridge,
MA, USA)
1:75, 4uC ON PBS. EnVision+ system HRP (+DAB), for rabbit
primary antibody detection (Dako North
America, Carpintera, CA, USA).
Rabbit polyclonal anti-human PAI-1
(BT-BS3503, Nordic BioSite,
Täby, Sweden)
1:100, 4uC ON PBS. EnVision+ system HRP (+DAB), for rabbit
primary antibody detection (Dako North
America, Carpintera, CA, USA).
Mouse monoclonal anti-human
PAI-1 (#3785, Sekisui Diagnostica
Stamford, CT, USA)
1:10 Wash buffer A (as described above).
Assay buffer (PBSw/1% BSA, 0.3%
Tween-20, pH 7.2). Wash buffer B
(as described above).
EnVision+ Dual Link system HRP (+DAB), for
rabbit and mouse primary antibody
detection (Dako North America, Carpintera,
CA, USA).
Anti-Ki67 (790–4286, Ventana
Medical systems, Inc., Tucson,
AZ, USA)
According to instruction
from Ventana.
According to instruction from Ventana. Ventana iView DAB detection kit
(cat.no. 760-09, Ventana Medical systems,
Inc., Tucson, AZ, USA).
Anti-Pan-Cytokeratin, AE1/AE2/PCK26
(760–2135, Ventana Medical systems,
Inc., Tucson, AZ, USA)
According to instruction
from Ventana.
According to instruction from Ventana. Ventana iView DAB detection kit
(cat.no. 760-09, Ventana Medical systems,
Inc., Tucson, AZ, USA).
*abbreviations used: ON, overnight; RT, room temperature; HRP, Horseradish peroxidase; DAB, diaminobenzidine; PBS, Phosphate buffered saline; BSA, bovine serum
albumin.
doi:10.1371/journal.pone.0101895.t001
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Staining patterns
Immunohistochemical staining of TMAs from the 115 patients
included in the study was conducted. uPAR staining was found to
be heterogeneously distributed within the tumour tissue, with most
of the uPAR staining seen in the centre of the tumour islands,
locating mainly to highly differentiated cells and somewhat less to
the basaloid cells (Figure 1A). PAI-1 and uPA staining was equally
distributed throughout the tumour tissue (Figure 1B and 1C). The
staining was found mostly in the cytoplasm of the cancer cells, but
some tumours also showed areas with membrane staining. All
three antibodies also stained stromal cells to a varying degree.
Figure 2 shows in more detail that uPAR staining could also be
detected at the plasma membrane (Figure 2A) and in the nucleus
(Figure 2B). The nuclear staining was not included in the scoring
since it was only found in a few cores. Both uPAR and PAI-1
staining showed an inter-tumour variety that was easy to score,
and typical examples of tumours with high and low scores are
shown in figure 3. The average score for uPAR in the low
expression group was 3.46 and 8.22 for the high expression group.
For PAI-1, the average score for the low expression group was 3.74
and 6.80 for the high expression group.
Staining of normal buccal mucosa tissue (n = 5) revealed that
although there was some variation between the different samples,
the staining intensity for both uPAR and PAI-1 was weak to
moderate in the normal epithelium and the average score was 3.64
for uPAR and 4.42 for PAI-1 (Figure 4). The cut-off value used to
distinguish between the low- and high expression groups was based
on the median value of the final scores for each marker and was
5.63 for uPAR and 5.25 for PAI-1. Hence, the cut-off values for
both uPAR and PAI-1 were higher than the average score of the
normal tissue. Ki-67 staining was found exclusively in the nucleus
(data not shown).
Disease specific death in relation to biomarkers
The four biomarkers were tested in a univariate analysis for
correlation with disease specific death within 5 years for all cases.
None of the markers displayed any statistically significant
association with disease specific death (data not shown). However,
for patients with T1 tumours without lymph node metastasis
(T1N0) at time of diagnosis, low uPAR expression was significantly
(p = 0.031) associated with 5 year disease specific death (Figure 5A).
A similar association was also found for expression of PAI-1
(p = 0.021)(Figure 5B), while neither uPA nor Ki-67 expression
were associated with disease specific death (Figure 5C and D).
Furthermore, uPAR and PAI-1 expression correlated signifi-
cantly with each other in the T1N0 tumours (Spearman’s Rho
correlation coefficient = 0.566, p = 0.003)(Figure 6). There was no
statistically significant correlation between uPAR and PAI-1 when
analysing the whole cohort (Spearman’s Rho correlation coeffi-
cient = 0.145, p = 0.127). In order to assess for confounding
factors, the distribution of low and high expression of uPAR and
PAI-1 in relation to gender, tumour differentiation and the OSCC
risk factors smoking and alcohol consumption, were analysed by a
Pearson’s Chi square test (Table 2). None of the factors were found
to be correlated with the expression levels of uPAR or PAI-1.
According to the pathology reports, the resection margins were
clear for all of the T1N0 patients, except for four patients where
the available information was inconclusive. All of these four
patients survived more than 5 years. Eight of the T1N0 patients
were treated with surgery only, the remaining received both
surgery and radiotherapy. Two thirds of the T1N0 tumours were
localized to the mobile tongue, while the remaining tumours were
localized to the floor of mouth (N = 3), gingival rim (N = 3), bucca
(N = 2), or soft palate (N = 1). All of the patients suffering a disease
specific death (N = 4), died due to incurable lymph node
metastasis. Two of those had elective neck dissection as part of
the primary surgical treatment, while the other two did not.
Hence, there was no correlation between surgical margins, tumour
localization or treatment, with outcome or expression of uPAR or
PAI-1.
Discussion
Although the prognosis in OSCC is mainly determined by the
stage of the tumour at presentation [2,6], there is a need for
reliable prognostic biomarkers that can be used for stratification of
treatment options within subgroups of patients.
For OSCC in general, patients with small tumours have a better
prognosis than patients with more advanced disease. Small
tumours can however behave aggressively, and also in cases
where no lymph node metastasis are found at diagnosis, the
outcome is unpredictable [1]. The treatment options are surgery
and/or radiotherapy. The treatment has major side effects that
often reduce the patients’ quality of life permanently. For patients
with T1 tumours without lymph node metastasis (T1N0) the
prognosis is particularly good. Nevertheless, the challenge is to
cure the patient without overtreating. In Scandinavia, the
Figure 1. Staining pattern for uPAR, PAI-1 and uPA in OSCC.
Representative photomicrographs of tissue microarray sections stained
for the markers A) uPAR, B) PAI-1 and C) uPA. Positive staining is seen
as brown colour, nuclei are stained blue with haematoxylin. Scale-
bar = 50 mm. T = Tumour. S = Stroma.
doi:10.1371/journal.pone.0101895.g001
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treatment of choice for this group is surgery in the majority of
cases. However, the fact that a large number of occult metastases
are found in patients classified as N0 [7,8,38], prompts the need
for tools to choose between ‘‘watchful waiting’’ or more extensive
treatment. Advanced surgery with elective neck dissection is often
performed or post-surgery radiotherapy is given because surgeons
do not dare to refrain from treatment. The results provided in this
study show that uPAR and PAI-1 correlate with disease specific
death for patients with T1N0 tumours (Figure 5), and thus are
good candidates for biomarkers that could aid in the decision-
making.
In our samples, most of the uPAR, PAI-1 and uPA staining were
found to be cytoplasmic or at the cell membrane (Figure 1). This is
in accordance with the previously described localizations of these
proteins [12,18,27,29,39]. In some patients, a few cells displayed
nuclear uPAR localization (Figure 2). Similar nuclear immunore-
activity has been reported in pancreatic cancer [30], however the
significance of this observation has not been determined. Thus,
further studies are needed to clearly demonstrate nuclear
localization of uPAR and the role it might have in the nucleus.
uPAR expression was also significantly correlated with PAI-1
expression in T1N0 tumours (figure 6). This is in partial agreement
with results from Lindberg et al. who analysed 20 cases of incipient
OSCC and found that both uPAR and PAI-1, together with
laminin c2, were expressed in early invasive OSCC [18]. Using
the R2 anti-uPAR antibody, they also report uPAR staining in
stromal macrophages and fibroblasts surrounding tumours with
low grade of invasion. In tumours with a higher grade of invasion,
but not diffuse invasion, uPAR expression was found in both
stromal- and cancer cells. In contrast, PAI-1 was found only in the
cancer cells and not in any stromal cells. Thus, they suggest that
PAI-1 is a better marker for initial OSCC invasion than uPAR.
Figure 2. Cytoplasmic and membrane staining of uPAR. Representative photomicrographs of tissue microarray sections stained for uPAR,
showing typical A) membrane and B) cytoplasmic localized staining of the tumour cells. Scalebar = 50 mm. Positive uPAR staining is seen as brown
colour, nuclei are stained blue with haematoxylin.
doi:10.1371/journal.pone.0101895.g002
Figure 3. Staining intensity of uPAR and PAI-1 in OSCC. Representative photomicrographs of tissue microarray cores showing strong and
weak staining for uPAR and PAI-1 in tumour islands: A) strong uPAR staining, B) weak uPAR staining, C) strong PAI-1 staining, and D) weak PAI-1
staining. Positive uPAR and PAI-1 staining is seen as brown colour, nuclei are stained blue with haematoxylin. Scalebar = 100 mm. T = Tumour.
S = Stroma.
doi:10.1371/journal.pone.0101895.g003
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We stained normal buccal mucosa tissue and found that both
uPAR and PAI-1 were weakly expressed in the epithelial layer.
The average score of both were lower than the cut-off values used
to separate the low and the high expressing tumours of both
markers. Thus, the level of uPAR and PAI-1 in the tumours
belonging to the low expression group is similar to the levels in
Figure 4. Staining of uPAR and PAI-1 in normal buccal mucosa tissue. Representative photomicrographs of normal buccal mucosa tissue
showing weak staining for uPAR (A) and PAI-1 (B) in the epithelial layer. Positive staining is seen as brown colour, nuclei are stained blue with
haematoxylin.
doi:10.1371/journal.pone.0101895.g004
Figure 5. Disease specific survival of patients with T1N0 tumours. Kaplan-Meier survival plot showing probability for a disease specific
survival based on A) uPAR, B) PAI-1, C) uPA and D) Ki-67 expression and related to months after diagnosis. Total number of patients included in the
analysis was 27 for uPAR and Ki-67, and 26 for PAI-1 and uPA. *; p,0.05 was regarded as statistically significant.
doi:10.1371/journal.pone.0101895.g005
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normal buccal mucosa tissue. Nozaki et al. analysed 34 primary
oral cancers and found that both uPAR (using the #3936 anti-
uPAR antibody) and PAI-1 (using the MAI-11 anti-PAI-1
antibody) were expressed in 29.4% of the cases [12]. Although
they found that fewer tumours were positive for uPAR and PAI-1,
they also found a significant correlation between the expression of
these proteins and mode of invasion. In our study, the use of TMA
did not allow the evaluation of invasion pattern, hence further
studies on whole tumour sections are needed in order to analyse
this association in our material.
Figure 6. Correlation between uPAR and PAI-1 expression in T1N0 tumours. The correlation between the final scores of uPAR and PAI-1 in
T1N0 tumours (N = 26) are presented in a Scatter plot (Spearman’s Rho correlation coefficient = 0.566, p = 0.003). The regression line and the 95%
confidence interval lines are indicated.
doi:10.1371/journal.pone.0101895.g006
Table 2. Distribution of low and high expression of uPAR and PAI-1 in relation to gender, tumour differentiation and the known
OSCC risk factors smoking and alcohol consumption.
uPAR PAI-1
low high p* low high p*
Gender
Men 11 (58%) 3 (38%) 0.333 7 (54%) 6 (46%) 0.695
Women 8 (42%) 5 (62%) 6 (46%) 7 (54%)
Tumour differentiation
Well 10 (53%) 3 (38%) 0.556 6 (46%) 7 (54%) 0.584
Moderate 8 (42%) 5 (62%) 6 (46%) 6 (46%)
Poor 1 (5%) 0 (0%) 1 (8%) 0 (0%)
Smoking
Never/previous 10 (53%) 2 (25%) 0.187 5 (38%) 6 (46%) 0.691
Smoker/unknown1 9 (47%) 6 (75%) 8 (62%) 7 (54%)
Alcohol
Never/,once a week 14 (74%) 5 (62%) 0.561 8 (62%) 10 (77%) 0.395
.once a week/daily/unknown2 5 (26%) 3 (38%) 5 (38%) 3 (23%)
Total number of patients included in the analysis was 27 for uPAR and 26 for PAI-1.
*Pearson’s Chi square test. p,0.05 was regarded as statistically significant.
1Number of unknown is 1.
2Number of unknowns is 3.
doi:10.1371/journal.pone.0101895.t002
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uPAR has previously been reported to correlate with overall 5
year survival in a Japanese cohort of 54 patients [13]. Bacchiocchi
et al. also found low uPAR expression to correlate with increased
overall survival in histological well differentiated OSCC tumours
(G1, 2003 WHO classification), but not in more poorly
differentiated (G2 or G3) tumours [39]. Their cohort consisted
of 189 patients where 77 were G1 tumours. Of these, 41 were
classified as TNM stage I, thus more than half of the cases were
T1N0M0. Thus, together with our results, this strongly suggests
that uPAR should be analysed further as a prognostic biomarker
for early stage tumours in OSCC.
PAI-1 has been proposed as a prognostic marker linked to poor
prognosis in several cancers [40], including in OSCC [16,18]. In
breast cancer, PAI-1 together with uPA, have been convincingly
shown to be strong prognostic markers, have recently reached
‘‘level-of-evidence 1’’ and are recommended in clinical use as a
stratification parameter for treatment of node-negative breast
cancer [41]. In their study, the determination of uPA and PAI-1
levels was done by certified ELISA tests on extracts of fresh-frozen
primary tumour tissue and not by IHC [42].
The Ki-67 proliferation marker is in use to predict prognosis in
several cancer types, although with some controversy [5,43]. Also
for OSCC there is no consensus for Ki-67 being a prognostic
marker. Gonzalez-Moles et al. showed in a Spanish cohort of 65
patients that Ki-67 lacks prognostic value [44], whereas it was
recently reported that high Ki-67 was a marker for good prognosis
in a Canadian cohort of 121 patients [45]. Our data showed no
statistically significant correlation with Ki-67 and survival in any of
the subgroups analysed. As stated in a review by Schliephake [10],
only 12 out of 23 reports on proliferation markers were associated
with prognosis. Therefore, high Ki-67 score should not be used to
support a decision for further treatment of OSCC patients.
In conclusion, our results show that patients with T1N0
tumours with low expression of uPAR and PAI-1 have decreased
risk of disease specific death. However, since our present cohort of
these tumours is relatively small, further studies on larger cohorts
must be performed in order to determine the use of uPAR and
PAI-1 as prognostic markers and tools for decision-making with
regards to treatment options.
Supporting Information
Figure S1 Specificity of the anti-uPAR antibody
(#3936). Photomicrographs of tissue microarray sections stained
for uPAR. A) The uPAR antibody was incubated in the presence
of recombinant His-tagged uPAR, antibody-antigen complexes
were removed by precipitation and remaining unbound material
was used for immunohistochemical staining of the tissue micro-
array section. B) The uPAR antibody received the same pre-
treatment as in a), except that the antibody was incubated without
His-tagged recombinant uPAR. C) The antibody received no pre-
treatment. D) Western blot showing uPAR expression in whole
cell lysates from the cell lines U937 (human) and GD25 (murine).
Lane 1: non-stimulated U937 cells, lane 2: U937 cells stimulated
with 200 nM PMA for 24 hours, lane 3: U937 cells stimulated
with 200 nM PMA for 48 hours, lane 4: GD25 cells, lane 5: GD25
cells stably overexpressing human uPAR. Left panel: The uPAR
antibody received the same pre-treatment as described in b). Right
panel: The uPAR antibody was pre-incubated with the presence of
recombinant His-tagged uPAR, as described in a).
(TIF)
Figure S2 Specificity of the anti-uPA antibody
(Ab24121). Photomicrographs of pancreatic cancer sections
immunohistochemically stained for uPA. A) Strong uPA expres-
sion in pancreatic cancer with lack of staining in nerve (asterix). B)
uPA expression in pancreatic cancer, but not in normal ducts
(asterix). C) uPA expression in pancreatic cancer, but negative in
benign pancreatic tissue (asterix).
(TIF)
Figure S3 Specificity of the anti-PAI-1 antibody (BT-
BS3505). Placenta tissue was stained with two different PAI-1
antibodies; #3785, used to stain the TMAs, and BS3505. A:
Cytotrophoblasts present in the maternal plate of the placenta
were positively stained using the anti-human PAI-1 antibody
(#3785), while the surrounding tissue was negative. B: Placental
tissue stained with the anti-human PAI-1 antibody (BT-BS3505)
showed similar positive staining patterns of the cytotrophoblasts in
the placenta plate as the #3785 antibody.
(TIF)
Table S1 Disease specific death (DSD) for all cases
(N = 115) in relation to clinicopathological variables.
(PDF)
Information S1 Specificity of antibodies. Materials, meth-
ods and results for the verification of the specificities of the
antibodies used.
(PDF)
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